TESARO Announces Data Presentations at the 2019 SGO Annual Meeting on Women’s Cancer
March 05, 2019 07:30 ET
|
TESARO, Inc.
WALTHAM, Mass., March 05, 2019 (GLOBE NEWSWIRE) -- TESARO, an oncology-focused business within GSK, today announced that data for dostarlimab (anti-PD-1 antibody, formerly TSR-042) and Zejula®...
Actor Scott Foley and TESARO Team Up to Empower Ovarian Cancer Care Partners Through New Phase of Not on My Watch Movement
February 26, 2019 07:30 ET
|
TESARO, Inc.
WALTHAM, Mass., Feb. 26, 2019 (GLOBE NEWSWIRE) -- TESARO, Inc., an oncology-focused business within GSK, announced today that acclaimed actor Scott Foley (TV’s Felicity, Scandal and the new ABC...
TESARO, Inc. Provides Notice of Fundamental Change, Conversion Rate Adjustment pursuant to Make-Whole Adjustment Event and Supplemental Indenture
January 24, 2019 08:00 ET
|
TESARO, Inc.
WALTHAM, Mass., Jan. 24, 2019 (GLOBE NEWSWIRE) -- TESARO, Inc. (the “Company” or “TESARO”), an oncology-focused biopharmaceutical company, today announced that pursuant to the terms of the Indenture...
TESARO, Inc. Gives Notice of Anticipated Make-Whole Adjustment Event to Holders of Its Convertible Senior Notes
December 04, 2018 16:15 ET
|
TESARO, Inc.
WALTHAM, Mass., Dec. 04, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that, pursuant to the terms of the indenture (the...
GSK reaches agreement to acquire TESARO, an oncology focused biopharmaceutical company
December 03, 2018 07:04 ET
|
TESARO, Inc.
LONDON and WALTHAM, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE/NYSE: GSK) and TESARO Inc (NASDAQ: TSRO) today announced that the Companies have entered into a definitive...
TESARO Announces Immuno-Oncology Data Presentations at SITC 2018 Annual Meeting
November 09, 2018 15:41 ET
|
TESARO, Inc.
Initial data from AMBER trial of TSR-022 (anti-TIM-3) in combination with TSR-042 (anti-PD-1) demonstrated clinical activity in patients who have progressed following anti-PD-1 treatmentTSR-042...
TESARO Announces Third-Quarter 2018 Operating Results
November 01, 2018 16:05 ET
|
TESARO, Inc.
ZEJULA® Q3 net sales totaled $63 million compared to $39 million for Q3 2017Top-line results for PRIMA trial of ZEJULA monotherapy for first-line ovarian cancer patients regardless of BRCA mutation...
The Foundation for Women’s Cancer and TESARO Partner on the Race to End Women’s Cancer for 3rd Year
October 30, 2018 08:05 ET
|
TESARO, Inc.
CHICAGO and WALTHAM, Mass., Oct. 30, 2018 (GLOBE NEWSWIRE) -- The Foundation for Women’s Cancer (FWC), the official foundation of the Society of Gynecologic Oncology (SGO), and TESARO, Inc....
TESARO Announces Achievement of ZEJULA Prostate Cancer Development Milestones by Janssen
October 29, 2018 08:00 ET
|
TESARO, Inc.
WALTHAM, Mass., Oct. 29, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today announced the achievement of development milestones that trigger...
TESARO and Actress Cobie Smulders Launch Not on My Watch, a National Movement to Empower the Ovarian Cancer Community
October 24, 2018 08:00 ET
|
TESARO, Inc.
Not on My Watch Aims to Shine a Light on the Importance of an Informed, Proactive Approach to Treatment WALTHAM, Mass., Oct. 24, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an...